Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482935 | 0.72 | BRD4 (0.33) | BRD4ALDH1A1 | |
| SCHEMBL482473 | 0.71 | ABCB1 (0.40) | BRD4HPGD | |
| SCHEMBL482790 | 0.70 | PTGDR2 (0.39) | BRD4ALDH1A1 | |
| SCHEMBL482835 | 0.67 | SMN1; SMN2 (0.38) | BRD4KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL482403 | 0.62 | BRD4 (0.41) | BRD4 | |
| SCHEMBL482489 | 0.58 | BRD4 (0.51) | BRD4 | |
| SCHEMBL2222843 | 0.57 | PSEN1 (0.35) | ALDH1A1LMNAMAPT | |
| SCHEMBL17312362 | 0.56 | KDM4E (0.44) | KDM4EALDH1A1HPGD | |
| SCHEMBL5835884 | 0.55 | BRD4 (0.53) | BRD4LMNA | |
| SCHEMBL5835879 | 0.55 | BRD4 (0.53) | BRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | BRD4 1271/4885KDM4E 1441/4885ALDH1A1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.